Capella BioScience Overview
- Founded
-
2014

- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
Capella BioScience General Information
Description
Developer of monoclonal antibody medicines (mAbs) intended to discover, develop, and commercialize medicines based on mAbs therapeutics. The company's medicines leverage novel technologies to develop therapeutics for oncology and autoimmune disease, enabling researchers to research the latest medical technology-based drugs.
Contact Information
Website
www.capellabioscience.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Biotechnology
Acquirer
Primary Office
- 158-160 North Gower Street
- London NW1 2ND
- England, United Kingdom
Capella BioScience Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
5. Merger/Acquisition | 16-Feb-2021 | 000.00 | Completed | Clinical Trials - General | ||
4. Later Stage VC | 24-Sep-2020 | 00.00 | 000.00 | 0000 | Completed | Clinical Trials - General |
3. Later Stage VC | 16-Aug-2019 | 00.00 | 000.00 | 000.00 | Completed | Clinical Trials - General |
2. Early Stage VC (Series A) | 03-Apr-2016 | $15.7M | $18.1M | Completed | Pre-Clinical Trials | |
1. Seed Round | 22-Dec-2014 | $2.35M | $2.35M | Completed | Startup |
Capella BioScience Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
B Shares | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 | |
Preference | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 | |
A Shares | 2,171,715 | $0.001306 | $2.59 | $2.59 | 1x | $2.59 | 1.73% | |
Seed | 1,500,000 | $0.001306 | $1.31 | $1.31 | 1x | $1.31 | 17.12% |
Capella BioScience Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details

Developer of monoclonal antibody medicines (mAbs) intended to discover, develop, and commercialize medicines based on mA
Drug Discovery
London, United Kingdom
000.00
000000&0
000.00
Capella BioScience Competitors (39)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Kineta | Venture Capital-Backed | Seattle, WA | 00 | 00000 | 000000000 | 00000 |
000000 | Venture Capital-Backed | Lebanon, NH | 000 | 00000 | 00000000000 | 00000 |
00000000 | Venture Capital-Backed | Middleton, WI | 00 | 000.00 | 0000000000 0 | 000.00 |
000000000 | Formerly VC-backed | Gaithersburg, MD | 00 | 00000 | 00000000 | 00000 |
00000 000000000000 | Venture Capital-Backed | Hamburg, Germany | 00 | 000.00 | 00000000000 | 000.00 |
Capella BioScience Patents
Capella BioScience Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20190315876-A1 | Antigen binding molecules that bind light | Pending | 24-Jan-2018 | 00000000000 | |
GB-2566389-A | Antigen binding molecules that bind light | Granted | 24-Jan-2017 | 00000000000 | 0 |
JP-2020505465-A | Antigen binding molecule that binds to light | Pending | 24-Jan-2017 | 00000000000 | |
GB-201701194-D0 | Antigen binding molecules that bind light | Ceased | 24-Jan-2017 | 00000000000 | |
GB-201820446-D0 | Antigen binding molecules that bind light | Granted | 24-Jan-2017 | C07K16/2875 |
Capella BioScience Former Investors (7)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Advent Life Sciences | Venture Capital | Minority | 000 0000 | 000000 0 | |
DCVC | Venture Capital | Minority | 000 0000 | 000000 0 | |
Farzad Nazem | Angel (individual) | Minority | 000 0000 | 000000 0 | |
Index Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
Lux Capital | Venture Capital | Minority | 000 0000 | 000000 0 |